Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jun;25(6):759-765.
doi: 10.1111/hiv.13633. Epub 2024 Mar 15.

Early HIV viral suppression associated with subsequent 12-month treatment success among people living with HIV in South Africa

Affiliations
Randomized Controlled Trial

Early HIV viral suppression associated with subsequent 12-month treatment success among people living with HIV in South Africa

Lauren R Violette et al. HIV Med. 2024 Jun.

Abstract

Background: We analyzed the STREAM (Simplifying HIV TREAtment and Monitoring) study to determine risk factors associated with HIV viraemia and poor retention 18 months after initiation of antiretroviral therapy (ART).

Methods: The STREAM study was an open-label randomized controlled trial in Durban, South Africa, that enrolled 390 people living with HIV presenting for their first HIV viral load measurement ~6 months after ART initiation. We used modified Poisson regression with robust standard errors to describe associations between baseline characteristics and three HIV outcomes 18 months after ART initiation: HIV viraemia (>50 copies/mL), poor retention in HIV care, and a composite outcome of poor retention in care and/or HIV viraemia.

Results: Approximately 18 months after ART initiation, 45 (11.5%) participants were no longer retained in care and 43 (11.8%) had viraemia. People with CD4 counts <200 and those with viraemia 6 months after ART initiation were significantly more likely to have viraemia 18 months after ART initiation (adjusted relative risk [aRR] 4.0; 95% confidence interval [CI] 2.1-7.5 and aRR 5.5; 95% CI 3.3-9.0, respectively). People who did not disclose their HIV status and had viraemia after ART initiation were more likely to not be retained in care 12 months later (aRR 2.6; 95% CI 1.1-6.1 and aRR 2.2; 95% CI 1.0-4.8). People with a CD4 count <200 and those with viraemia were more likely to not achieve the composite outcome 18 months after ART initiation.

Conclusions: Viraemia after ART initiation was the strongest predictor of subsequent viraemia and poor care retention. Understanding early indicators can help target our interventions to better engage people who may be more likely to experience persistent viraemia or disengage from HIV care.

Keywords: HIV; point‐of‐care; retention in care; viral failure; viral load monitoring.

PubMed Disclaimer

References

    1. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. Accessed May 1, 2023. https://www.who.int/publications/i/item/9789240031593 - PubMed
    1. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013; 27:973–9. doi: 10.1097/QAD.0b013e32835cae9c. - DOI - PubMed
    1. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830–839. doi: 10.1056/NEJMoa1600693. - DOI - PMC - PubMed
    1. South Africa data. UNAIDS. Updated 2021. Accessed May 1, 2023. https://www.unaids.org/en/regionscountries/countries/southafrica
    1. Drain PK, Dorward J, Violette LR et al. Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-lab, non-inferiority, randomised controlled trial. Lancet HIV 2020;7:e229–37. doi: 10.1016/S2352-3018(19)30402-3. - DOI - PMC - PubMed

Publication types

Substances